AU2017341936B2 - Modular tetravalent bispecific antibody platform - Google Patents
Modular tetravalent bispecific antibody platform Download PDFInfo
- Publication number
- AU2017341936B2 AU2017341936B2 AU2017341936A AU2017341936A AU2017341936B2 AU 2017341936 B2 AU2017341936 B2 AU 2017341936B2 AU 2017341936 A AU2017341936 A AU 2017341936A AU 2017341936 A AU2017341936 A AU 2017341936A AU 2017341936 B2 AU2017341936 B2 AU 2017341936B2
- Authority
- AU
- Australia
- Prior art keywords
- amino acid
- seq
- linker
- cdrs
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2025200665A AU2025200665A1 (en) | 2016-10-14 | 2025-01-31 | Modular tetravalent bispecific antibody platform |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408271P | 2016-10-14 | 2016-10-14 | |
| US62/408,271 | 2016-10-14 | ||
| PCT/US2017/056814 WO2018071913A2 (en) | 2016-10-14 | 2017-10-16 | Modular tetrameric bispecific antibody platform |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2025200665A Division AU2025200665A1 (en) | 2016-10-14 | 2025-01-31 | Modular tetravalent bispecific antibody platform |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017341936A1 AU2017341936A1 (en) | 2019-04-04 |
| AU2017341936B2 true AU2017341936B2 (en) | 2024-10-31 |
Family
ID=60327374
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017341936A Active AU2017341936B2 (en) | 2016-10-14 | 2017-10-16 | Modular tetravalent bispecific antibody platform |
| AU2025200665A Pending AU2025200665A1 (en) | 2016-10-14 | 2025-01-31 | Modular tetravalent bispecific antibody platform |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2025200665A Pending AU2025200665A1 (en) | 2016-10-14 | 2025-01-31 | Modular tetravalent bispecific antibody platform |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20200017588A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3526257A2 (cg-RX-API-DMAC10.html) |
| JP (3) | JP7269167B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN110214152B (cg-RX-API-DMAC10.html) |
| AU (2) | AU2017341936B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3038504A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018071913A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3031194A1 (en) * | 2016-07-22 | 2018-01-25 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
| EP3526257A2 (en) * | 2016-10-14 | 2019-08-21 | Dana-Farber Cancer Institute, Inc. | Modular tetravalent bispecific antibody platform |
| WO2018145075A1 (en) * | 2017-02-06 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for augmenting antibody mediated receptor signaling |
| EP3880247A4 (en) * | 2018-11-13 | 2022-10-26 | JN Biosciences, LLC | Bispecific antibodies for activation of immune cells |
| JP2022510218A (ja) * | 2018-11-30 | 2022-01-26 | メモリアル スローン ケタリング キャンサー センター | ヘテロ二量体四価特異性抗体およびこれらの使用 |
| CA3159308A1 (en) * | 2019-12-02 | 2021-06-10 | Wayne A. Marasco | Antibodies against pd-l1 and methods of use thereof |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业(上海)股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| WO2021226984A1 (zh) * | 2020-05-15 | 2021-11-18 | 三生国健药业(上海)股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| WO2023034288A1 (en) | 2021-08-31 | 2023-03-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treatment of autoimmune disorders and cancer |
| WO2023097024A1 (en) | 2021-11-24 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
| AU2023232045A1 (en) | 2022-03-09 | 2024-09-26 | Dana-Farber Cancer Institute, Inc. | Genetically engineered b cells and methods of use thereof |
| CA3263665A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Anti-CLDN4 antibodies and their methods of use |
| WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
| CN121399164A (zh) * | 2023-06-20 | 2026-01-23 | 戴纳立制药公司 | 双重转运体及使用方法 |
| WO2026117666A1 (en) * | 2024-11-26 | 2026-06-04 | Dana-Farber Cancer Institute, Inc. | Bispecific antibodies for treating cancer |
| WO2026117664A1 (en) * | 2024-11-26 | 2026-06-04 | Dana-Farber Cancer Institute, Inc. | Engineered cells and uses thereof for treating cancer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8084026B2 (en) * | 2005-01-05 | 2011-12-27 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| WO2013096346A1 (en) * | 2011-12-22 | 2013-06-27 | Development Center For Biotechnology | Bispecific t-cell activator antibody |
| WO2013173820A2 (en) * | 2012-05-18 | 2013-11-21 | Scott & White Healthcare | Bispecific scfv immunofusion (bif) |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| DE4118120A1 (de) * | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| WO2003002144A1 (en) * | 2001-06-26 | 2003-01-09 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| CN1914226B (zh) | 2003-11-25 | 2012-02-01 | 达纳-法伯癌症研究院有限公司 | SARS-CoV抗体及其使用方法 |
| EP1695093A1 (en) * | 2003-12-05 | 2006-08-30 | multimmune GmbH | Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases |
| US8329178B2 (en) | 2005-02-18 | 2012-12-11 | Dana-Farber Cancer Institute, Inc. | Antibodies against CXCR4 and methods of use thereof |
| EP1979379B1 (en) | 2005-12-02 | 2013-09-18 | Dana-Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| EP3524619A1 (en) | 2007-12-06 | 2019-08-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
| WO2009086514A1 (en) | 2007-12-28 | 2009-07-09 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| JP2011524966A (ja) * | 2008-02-22 | 2011-09-08 | ダウ グローバル テクノロジーズ エルエルシー | 熱エネルギー貯蔵材料 |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| EP3957653A1 (en) | 2010-06-02 | 2022-02-23 | Dana Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| EP2543680A1 (en) * | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| CN103906533A (zh) * | 2011-11-07 | 2014-07-02 | 米迪缪尼有限公司 | 多特异性和多价结合蛋白及其用途 |
| CN104203981A (zh) * | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| EP2794662A1 (en) * | 2011-12-22 | 2014-10-29 | F.Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| AU2013256010B2 (en) | 2012-05-04 | 2018-01-04 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| EP2920210B1 (en) * | 2012-11-19 | 2017-08-30 | Baliopharm AG | Recombinant bispecific antibody binding to cd20 and cd95 |
| CN105530959B (zh) | 2013-03-15 | 2021-09-17 | 纪念斯隆-凯特琳癌症中心 | 多聚化技术 |
| EP4292657A3 (en) | 2013-03-15 | 2024-03-20 | Dana Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
| SG11201509566RA (en) | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
| AR097306A1 (es) * | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| KR20160122127A (ko) * | 2013-12-23 | 2016-10-21 | 자임워크스 인코포레이티드 | C-말단의 경쇄 폴리펩타이드 연장부를 포함하는 항체 및 이의 컨쥬게이트 및 이들의 사용방법 |
| EP3119804A2 (en) | 2014-03-19 | 2017-01-25 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
| WO2015164865A1 (en) | 2014-04-25 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof |
| PL3151921T3 (pl) * | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| WO2015197582A1 (en) | 2014-06-27 | 2015-12-30 | Innate Pharma | Monomeric multispecific antigen binding proteins |
| RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
| CA2962949C (en) | 2014-10-06 | 2024-03-05 | Dana-Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
| US11135282B2 (en) | 2015-04-08 | 2021-10-05 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
| EP3526257A2 (en) * | 2016-10-14 | 2019-08-21 | Dana-Farber Cancer Institute, Inc. | Modular tetravalent bispecific antibody platform |
| JP7649239B2 (ja) * | 2018-11-30 | 2025-03-19 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | キメラ抗原受容体ファクトリおよびその使用方法 |
-
2017
- 2017-10-16 EP EP17798026.5A patent/EP3526257A2/en active Pending
- 2017-10-16 US US16/340,878 patent/US20200017588A1/en not_active Abandoned
- 2017-10-16 JP JP2019520024A patent/JP7269167B2/ja active Active
- 2017-10-16 CN CN201780067582.7A patent/CN110214152B/zh active Active
- 2017-10-16 CA CA3038504A patent/CA3038504A1/en active Pending
- 2017-10-16 CN CN202510732184.9A patent/CN120795163A/zh active Pending
- 2017-10-16 AU AU2017341936A patent/AU2017341936B2/en active Active
- 2017-10-16 WO PCT/US2017/056814 patent/WO2018071913A2/en not_active Ceased
-
2023
- 2023-04-21 JP JP2023069848A patent/JP7796079B2/ja active Active
-
2025
- 2025-01-31 AU AU2025200665A patent/AU2025200665A1/en active Pending
- 2025-07-16 JP JP2025119440A patent/JP2025142045A/ja active Pending
- 2025-09-03 US US19/318,009 patent/US20260193357A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8084026B2 (en) * | 2005-01-05 | 2011-12-27 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| WO2013096346A1 (en) * | 2011-12-22 | 2013-06-27 | Development Center For Biotechnology | Bispecific t-cell activator antibody |
| WO2013173820A2 (en) * | 2012-05-18 | 2013-11-21 | Scott & White Healthcare | Bispecific scfv immunofusion (bif) |
Non-Patent Citations (2)
| Title |
|---|
| MÃ LLER ET AL: "A dimeric bispecific miniantibody combines two specificities with avidity.", FEBS LETTERS, vol. 432, no. 1-2, 1 July 1998 (1998-07-01), pages 45 - 49, XP055058073, ISSN: 0014-5793, DOI: 10.1016/S0014-5793(98)00829-1 * |
| Pohl, Stefanie Claudia, et al. "A cassette vector system for the rapid cloning and production of bispecific tetravalent antibodies." Antibodies vol 1(1), 2012, pg. 19-38. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019533675A (ja) | 2019-11-21 |
| CN110214152A (zh) | 2019-09-06 |
| EP3526257A2 (en) | 2019-08-21 |
| AU2025200665A1 (en) | 2025-04-10 |
| US20260193357A1 (en) | 2026-07-09 |
| JP7269167B2 (ja) | 2023-05-08 |
| CN120795163A (zh) | 2025-10-17 |
| WO2018071913A2 (en) | 2018-04-19 |
| US20200017588A1 (en) | 2020-01-16 |
| JP2023093642A (ja) | 2023-07-04 |
| WO2018071913A3 (en) | 2018-05-24 |
| AU2017341936A1 (en) | 2019-04-04 |
| CN110214152B (zh) | 2025-06-13 |
| JP2025142045A (ja) | 2025-09-29 |
| JP7796079B2 (ja) | 2026-01-08 |
| CA3038504A1 (en) | 2018-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7796079B2 (ja) | モジュラー四価二重特異性抗体プラットフォーム | |
| AU2022200257B2 (en) | Chimeric antigen receptors and methods of use thereof | |
| AU2019243453B2 (en) | Methods of making and using guidance and navigation control proteins | |
| AU2018360800B2 (en) | Chimeric antigen receptors specific for B-cell maturation antigen (BCMA) | |
| RU2753902C2 (ru) | Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1 | |
| CN111954680B (zh) | IL2Rβ/共同γ链抗体 | |
| CN109952112B (zh) | Cd123结合蛋白和相关的组合物和方法 | |
| KR20230024984A (ko) | Cd70-지시 암 면역요법용 유전적으로 변형된 자연 살해 세포 | |
| CN114585645A (zh) | 对杂合性丧失作出响应的细胞表面受体 | |
| AU2016334623A1 (en) | Bispecific antibodies with tetravalency for a costimulatory TNF receptor | |
| KR20180132751A (ko) | Bcma 결합 분자 및 그의 사용 방법 | |
| KR20230160874A (ko) | CD79b, CD20 및 CD3을 표적으로 하는 삼중특이적 항체 | |
| KR102960041B1 (ko) | Egfr 양성 암을 치료하기 위한 조성물 및 방법 | |
| CN111971303B (zh) | 抗cd27抗体及其用途 | |
| CN113423720A (zh) | CAR文库和scFv的制造方法 | |
| CN117460747A (zh) | 靶向CD79b、CD20和CD3的三特异性抗体 | |
| RU2843842C1 (ru) | Композиции и способы для лечения egfr-положительных форм рака | |
| RU2824896C2 (ru) | Способы получения и применения направляющих и навигационных контрольных белков | |
| RU2811457C2 (ru) | Белки управления, навигации и контроля и способ их получения и применения | |
| HK40026017A (en) | Methods of making and using guidance and navigation control proteins | |
| HK40026018A (en) | Guidance and navigation control proteins and method of making and using thereof | |
| HK40026018B (en) | Guidance and navigation control proteins and method of making and using thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |